Latest News

Phase 1b/2 findings showed that the investigational anti-amyloid monoclonal antibody ABBV-916 produced dose-dependent reductions in brain amyloid in adults with early Alzheimer disease, although development of the agent was discontinued before dose expansion because of sponsor business considerations.

In recognition of SMA Awareness Month, NeurologyLive® spoke with neuromuscular experts about how multidisciplinary care is built, where coordination breaks down, and what changes as patients live longer.

A phase 1 feasibility trial found that placing GammaTile radiation therapy directly into the surgical cavity during glioblastoma resection sharply reduced rapid early tumor regrowth compared with historical rates, setting up a phase 3 randomized trial.

In recognition of SMA Awareness Month, NeurologyLive® spoke with neuromuscular experts about how multidisciplinary care is built, where coordination breaks down, and what changes as patients live longer.

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology headlines you may have missed from last week, compiled into 1 place by the NeurologyLive® team.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric epilepsy care!

In honor of SMA Awareness Month, held annually throughout August, get caught up on the latest news in spinal muscular atrophy from 2026, 5 headlines compiled in one place by the NeurologyLive® team.

Findings from a phase 1 study showed that bilateral putaminal delivery of AAV2-GDNF using convection-enhanced delivery was well tolerated over 5 years, although exploratory clinical measures did not demonstrate significant improvements from baseline.

In recognition of SMA Awareness Month, held annually throughout August, NeurologyLive® reviews the investigational agents currently moving through clinical development for spinal muscular atrophy.

Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Jacqueline Rosenthal, MD, to discuss the medical uses of botulinum toxin across neurologic conditions, including chronic migraine and spasticity, as well as treatment expectations, shared decision-making, and common misconceptions surrounding Botox.

The phase 3 clinical program for salanersen, an investigational intrathecally administered antisense oligonucleotide, will test the efficacy of the agent across infants, adolescents and adults living with SMA.

Cellenkos’ investigational allogeneic, cord blood-derived T-regulatory cell therapy is being evaluated in a phase 1/1b study in ALS, with early findings showing reductions in plasma neurofilament light chain and increases in IL-10.